| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Targets: CB1 (cannabinoid receptor type 1, IC50 = 8.92 uM); SOS1-KRAS interaction (potential inhibitor); VEGFR2; PI3K/AKT/mTOR; MAPK. As a CB1 antagonist, Auriculasin blocks the effects of endocannabinoids at CB1 receptors. It also inhibits SOS1-KRAS interactions, which are critical for KRAS-driven cancers, and suppresses angiogenesis via VEGFR2 inhibition.
|
|---|---|
| ln Vitro |
In vitro, Auriculasin (IC50 = 8.92 uM) binds to CB1 and inhibits its activity. It effectively inhibits cell proliferation, induces apoptosis, and suppresses angiogenesis via inhibition of VEGFR2, PI3K/AKT/mTOR, and MAPK signaling pathways. It also promotes mitochondrial oxidative stress and ferroptosis. It exhibits potent antibacterial activity against multidrug-resistant E. coli strains by inhibiting bacterial DNA gyrase.
|
| ln Vivo |
No in vivo efficacy data have been published specifically for Auriculasin in animal models. However, based on its anticancer and anti-inflammatory activities, it is expected to have in vivo activity in xenograft models of KRAS-driven cancers, inflammatory disease models, and models of bacterial infection. Detailed animal studies have not been reported in the available literature.
|
| Enzyme Assay |
For cell-free binding assays (CB1): membranes prepared from CHO cells expressing human CB1 are incubated with varying concentrations of Auriculasin (0-100 uM) and the radioligand 3H-CP-55940 in binding buffer for 90 min at 30degC. Bound radioactivity is measured by filtration and scintillation counting. IC50 (8.92 uM) is calculated from dose-response curves. For SOS1-KRAS interaction assays: purified SOS1 and KRAS proteins are incubated with Auriculasin (0-100 uM) in the presence of nucleotide exchange factors, and KRAS activation is measured by fluorescence or ELISA. For antibacterial assays: broth microdilution according to CLSI guidelines.
|
| Cell Assay |
For cell-based assays: cancer cell lines (e.g., lung, colon, pancreatic, breast cancer cells) are seeded in 96-well plates and treated with Auriculasin (0-100 uM, 24-72 h). Cell viability is measured by MTT or CCK-8 assay. Apoptosis is assessed by Annexin V/PI flow cytometry. Angiogenesis is assessed using HUVEC tube formation assays. VEGFR2, PI3K/AKT/mTOR, and MAPK pathway proteins (p-AKT, p-ERK, p-mTOR) are measured by Western blot. ROS levels are measured by DCFH-DA fluorescence.
|
| Animal Protocol |
For in vivo animal studies: potential protocol involves xenograft mouse models bearing human lung, colon, or pancreatic cancer cells. Auriculasin would be administered intraperitoneally or orally (10-50 mg/kg) daily for 2-4 weeks. Tumor volume is measured by calipers, and tumor weights are recorded at endpoint. Tumor tissues are harvested for Western blot analysis of target pathways (p-AKT, p-ERK, p-VEGFR2) and Ki67 immunohistochemistry. For anti-inflammatory studies, carrageenan-induced paw edema or DSS-induced colitis models in mice may be used. No published data available.
|
| ADME/Pharmacokinetics |
PK properties of Auriculasin: As a natural flavonoid (MW 420.46, ClogP ∼3.7), expected PK in rodents: low oral bioavailability due to extensive first-pass metabolism (glucuronidation and sulfation), Cmax achieved 1-2 h after oral administration, plasma half-life 2-4 h. Tmax is 30-60 min. Volume of distribution is moderate. The compound is metabolized by phase II conjugating enzymes (UGTs, SULTs) and potentially by CYP450 enzymes. Excretion occurs primarily via bile and urine. No formal PK studies have been published.
|
| Toxicity/Toxicokinetics |
No toxicity data have been reported for Auriculasin. As a natural flavonoid, it is considered relatively safe. However, inhibition of CB1 may cause adverse effects, including nausea, vomiting, anxiety, and depression (since CB1 antagonists are known to have psychiatric side effects). No acute toxicity or LD50 studies have been published. The compound is for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
Auriculasin is a type of isoflavone compound. It has been reported to exist in apple wood (Maclura pomifera), large-leaved Fleming wood (Flemingia macrophylla), and other organisms with relevant data.
Auriculasin is a research compound not yet approved for clinical use. It is a natural product with multiple bioactivities, including CB1 antagonist activity, SOS1-KRAS interaction inhibition, and anticancer, anti-inflammatory, and antibacterial properties. It serves as a chemical probe for studying CB1 biology, KRAS-driven cancers, and ferroptosis. It also has potential as a lead compound for developing novel therapeutics for cancer, inflammation, and infectious diseases. It is also used as a reference standard in natural product research. |
| Molecular Formula |
C25H24O6
|
|---|---|
| Molecular Weight |
420.4545
|
| Exact Mass |
420.157
|
| CAS # |
60297-37-2
|
| PubChem CID |
5358846
|
| Appearance |
White to off-white solid powder
|
| Density |
1.314g/cm3
|
| Boiling Point |
668ºC at 760 mmHg
|
| Flash Point |
231.2ºC
|
| Index of Refraction |
1.644
|
| LogP |
5.269
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
792
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
PSEBCAMYGWGJMH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H24O6/c1-13(2)5-7-16-23-15(9-10-25(3,4)31-23)21(28)20-22(29)17(12-30-24(16)20)14-6-8-18(26)19(27)11-14/h5-6,8-12,26-28H,7H2,1-4H3
|
| Chemical Name |
7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3784 mL | 11.8920 mL | 23.7840 mL | |
| 5 mM | 0.4757 mL | 2.3784 mL | 4.7568 mL | |
| 10 mM | 0.2378 mL | 1.1892 mL | 2.3784 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
